Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Conferences
Videos
Webinars
Media & Press
Whitepapers
Advertising
Site Map
2023
March
02
Active surveillance on the rise for low-risk prostate cancer
Week in Review: Natera nabs commercial coverage | U.S. government’s mRNA vaccine investment | Could Medicare have saved millions on drug testing payments?
Electronic health record interventions reduce unnecessary urine culture orders, study finds
Sophia Genetics, Qiagen collaborate on next-generation sequencing for tumor analysis
Natera receives commercial payor coverage for molecular residual disease test
Page 1 of 1